American Journal of Epidemiology and Infectious Disease
ISSN (Print): 2333-116X ISSN (Online): 2333-1275 Website: Editor-in-chief: Apply for this position
Open Access
Journal Browser
American Journal of Epidemiology and Infectious Disease. 2015, 3(1), 1-9
DOI: 10.12691/ajeid-3-1-1
Open AccessArticle

Antibacterial, Anti-biofilm Activity of Some Non-steroidal Anti-Inflammatory Drugs and N-acetyl Cysteine against Some Biofilm Producing Uropathogens

Ahmed Mohsen1, Alyaa Gomaa1, Fatma Mohamed1, Roaa Ragab1, mennatallah Eid1, Al-Hussein Ahmed2, Areej Khalaf2, Mohamed Kamal1, Safaa Mokhtar1, Hadeer Mohamed1, Islam Salah1, Rania Abbas1, Sameh Ali3 and Rehab Mahmoud Abd El-Baky4,

1Undergraduate student, faculty of pharmacy, Minia University

2Undergraduate student, Faculty of science, Minia University

3Demonstrator of microbiology, Faculty of Pharmacy, Minia University

4Lecturer of microbiology, Faculty of Pharmacy, Minia University

Pub. Date: January 06, 2015

Cite this paper:
Ahmed Mohsen, Alyaa Gomaa, Fatma Mohamed, Roaa Ragab, mennatallah Eid, Al-Hussein Ahmed, Areej Khalaf, Mohamed Kamal, Safaa Mokhtar, Hadeer Mohamed, Islam Salah, Rania Abbas, Sameh Ali and Rehab Mahmoud Abd El-Baky. Antibacterial, Anti-biofilm Activity of Some Non-steroidal Anti-Inflammatory Drugs and N-acetyl Cysteine against Some Biofilm Producing Uropathogens. American Journal of Epidemiology and Infectious Disease. 2015; 3(1):1-9. doi: 10.12691/ajeid-3-1-1


Ureteral catheters are indispensable devices used in the management of ureteral obstruction. Although the stent is essential for treatment, it also has complications, which are encrustation, stone formation and biofilm formation. Biofilm infections result in a complication in the course of treatment, increasing the length of patients stay in hospital and overall cost. Catheter-associated infections are difficult to be treated with antibiotics and there is a need to change catheters due to the formation of biofilm on their surfaces. In this study, In this study, we examine the effect of some of prescribed drugs as NSAIDs and N-acetylcysteine on the adherence of S. aureus, K. pneumoniae, P. aeruginosa and Proteus mirabilis on the surface of catheters, and their effects on the preformed mature biofims. Also, we determine their antibacterial activity. The results showed that the tested agents had good antibacterial activity, a significant effect on the inhibition of adherence of the tested strains to plastic surfaces and a high disruptive effect on mature biofilms. In conclusion, the tested drugs can be used in the treatment of catheter-associated infections.

NSAIDs biofilm mucolytics adherence

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


Figure of 9


[1]  Pettit RK, Weber CA, Kean MJ, et al. Microplate Alamar Blue assay for Staphylococcus epidermidis biofilm susceptibility testing. Antimicrob Agents Chemother. 2005, 49: 2612-2617.
[2]  Flemming K, Klingenberg C, Cavanagh JP, et al. High in vitro antimicrobial activity of synthetic antimicrobial peptidomimetics against staphylococcal biofilms. J Antimicrob Chemother. 2009, 63: 136-145.
[3]  Lindsay D, von Holy A. Bacterial biofilms within the clinical setting: what healthcare professionals should know. J Hosp Infect. 2008, 64: 313-325.
[4]  Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002, 15: 167-193.
[5]  Chambers ST, Peddie B, Pithie A. Ethanol disinfection of plastic-adherent micro organisms. J Hosp Infect. 2006, 63: 193-196.
[6]  Frank KL, Reichert EJ, Piper KE, Patel R. In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates. Antimicrob Agents Chemother. 2007, 51: 888-895.
[7]  Gualtieri M, Bastide L, Villain-Guillot P, Michaux-Charachon S, Latouche J, Leonetti JP. In vitro activity of a new antibacterial rhodanine derivative against Staphylococcus epidermidis biofilms. J Antimicrob Chemother. 2006, 58: 778-783.
[8]  Jefferson KK. What drives bacteria to produce a biofilm? FEMS Microbiol Lett 2004; 236: 163-173.
[9]  Prüß BM, Besemann C, Denton A, Wolfe J. A complex transcription network controls the early stages of biofilm development by Escherichia coli. J Bacteriol. 2006, 188: 3731-3739.
[10]  An YH, Friedman RJ. Concise review of mechanisms of bacterial adhesion to biomaterial surfaces. J Biomed Mater Res. 1998, 43: 338-348.
[11]  Katsikogianni M, Missirlis YF. Concise review of mechanisms of bacterial adhesion to biomaterials and of techniques used in estimating bacteriaematerials interactions. Euro Cell Mater. 2004, 8: 37-57.
[12]  Cerca B, Martins S, Pier G, Oliveira R, Azevedo J. The relationship between inhibition of bacterial adhesion to a solid surface by sub-MICs of antibiotics and subsequent development of a biofilm. Res Microbiol. 2005, 156: 650-655.
[13]  Kinnari TJ, Peltonen LI, Kuusela P, Kiviahti J, Kononen M, Jero J. Bacterial adherence to titanium surface coated with human serum albumin. Otol Neurotol. 2005, 26: 380-384.
[14]  Kleinknecht D, Landais P, Goldfarb B. Analgesic and nonsteroidal anti-inflammatory drug-associated acute renal failure: a prospective collaborative study. Clin Nephrol. 1986, 25: 275-281.
[15]  Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ. Clinical implications of prostaglandin and thromboxane A2 formation (2). N Engl J Med. 1988, 319: 761-767.
[16]  Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int. 1987, 32: 1-12.
[17]  Huerta C, Castellsague J, Varas-Lorenzo C, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005, 45: 531-539.
[18]  Efrati S, Averbukh M, Berman S et al. N-Acetylcysteine ameliorates lithium-induced renal failure in rats. Nephrol Dial Transplant. 2005, 20: 65-70.
[19]  Efrati S, Dishy V, Averbukh M et al. The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. Kidney Int. 2003, 64: 2182-2187.
[20]  Feldman L, Efrati S, Dishy V et al. N-acetylcysteine ameliorates amphotericin-induced nephropathy in rats. Nephron Physiol. 2005, 99: 23-27.
[21]  DiMari J, Megyesi J, Udvarhelyi N, Price P, Davis R, Safirstein R. N-acetyl cysteine ameliorates ischemic renal failure. Am J Physiol. 1997, 272: F292-F298.
[22]  Mazzon E, Britti D, De Sarro A, Caputi AP, Cuzzocrea S. Effect of N-acetylcysteine on gentamicin-mediated nephropathy in rats. Eur J Pharmacol, 2001, 424: 75-83.
[23]  Marenzi G, Assanelli E, Marana I et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006; 354: 2773-2782.
[24]  Heyman SN, Goldfarb M, Shina A, Karmeli F, Rosen S. N-acetylcysteine ameliorates renal microcirculation: studies in rats. Kidney Int 2003, 63: 634-641.
[25]  Efrati S, Berman S, Siman-Tov Y, Lotan R, Averbukh Z, Weissgarten J and Golik A. N-acetylcysteine attenuates NSAID-induced rat renal failure by restoring intrarenal prostaglandin synthesis Nephrol Dial Transplant. 2007, 22: 1873-1881.
[26]  Christensen G.D., W.A. Simpson, J.A. Younger, L.M. Baddour, F.F. Barrett, D.M. Melton, et al. Adherence of coagulase negative Staphylococci to plastic tissue cultures: a quantitative model for the adherence of staphylococci to medical devices. J. Clin. Microbiol. 1985, 22: 996-1006.
[27]  Bennet J.V., Brodie J.L., Benner J.L., Kirby W.M.M., "Simplified accurate method for antibiotic assay of clinical specimens". Appl Microbiol. 1966, 14: p. 2170-2177.
[28]  Xiaogang L, Zhun Y and Jianping X. Quantitative variation of biofilms among strains in natural populations of Candida albicans. Microbiology 2003, 149: 353-362.
[29]  Soboh F, Khoury AE, Zamboni AC, Davidson D, Mittelman MW. Effects of ciprofloxacin and protamine sulfate combinations against catheter-associated Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother 1995, 39: 1281-1286.
[30]  Wojnicz D, Tichaczek-Goska D. Effect of sub-minimum inhibitory concentrations of ciprofloxacin, amikacin and colistin on biofilm formation and virulence factors of Escherichia coli planktonic and biofilm forms isolated from human urine. BJM 44, 1, 259-265 (2013).
[31]  Wang WH, Wong WM, Dailidiene D, Berg DE, Gu Q, Lai KC et al. Aspirin inhibits the growth of Helicobacter pylori and en-hances its susceptibility to antimicrobial agents. Gut. 2003 Apr; 52(4): 490-5.
[32]  Hersh EV, Hammond BF, Fleury AA. An-timicrobial activity of flurbiprofen and ibupro-fen in vitro against six common periodontal pathogens. J Clin Dent. 1991, 3(1): 1-5.
[33]  Olofsson AC, Hermansson M, Elwing H. N-acetyl-l-cysteine affects growth, extracellular polysaccharide production and bacterial biofilm formation on solid surfaces. Appl. Environ. Microb. 2003, 69: 4814-22.
[34]  Perez-Giraldo C, Rodriguez-Benito A, Moran FJ, Hurtado C, Blanco MT, Gómez-García AC. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. J Antimicrob chemoth. 1997, 39: 643-6.
[35]  Abbas Hisham A., Fathy M. Serry, Eman M. EL-Masry (2012) Combating Pseudomonas aeruginosa Biofilms by Potential Biofilm Inhibitors Asian J. Res. Pharm. Sci. 2012, Vol. 2: 66-72.
[36]  El-Rehewy M S K, El-Feky M A, Hassan MA, Abolella H A, Abolyosr A, Abd El-Baky R M and Gad G F In vitro Efficacy of Ureteral Catheters Impregnated with Ciprofloxacin, N acetylcysteine and their Combinations on Microbial Adherence Clinical Medicine: Urology 2009, 21-8.
[37]  El-Feky, M.A., El-Rehewy, M.S., Hassan, M.A., Abolella H.A., Abd El-Baky, R.M., and Gad, G.F. (2009). Effect of ciprofloxacin and N-acetylcysteine on bacterial adherence and biofilm formation on ureteral stent surfaces. Pol. J. Microbiol., 58(3), pp. 261-267.
[38]  Scholer DW, Boettcher I, Ku EC, Schweizer A. Pharmacology of diclofenac so-dium (Voltaren). Semin Arthritis Rheum. 1985, 15(2 Suppl 1): 61-4.
[39]  Zuniga JR, Malmstrom H, Noveck RJ, Campbell JH, Christensen S, Glickman RS, et al. Controlled phase III clinical trial of diclo-fenac potassium liquid-filled soft gelatin cap-sule for treatment of postoperative dental pain. J Oral Maxillofac Surg. 2010, 68(11): 2735-42.
[40]  Kubitzek F, Ziegler G, Gold MS, Liu JM, Ionescu E. Analgesic efficacy of low-dose dic-lofenac versus paracetamol and placebo in postoperative dental pain. J Orofac Pain. 2003 Summer; 17(3): 237-44.
[41]  Buyukkurt MC, Gungormus M, Kaya O. The effect of a single dose prednisolone with and without diclofenac on pain, trismus, and swelling after removal of mandibular third molars. J Oral Maxillofac Surg. 2006, 64(12): 1761-6.
[42]  Saatchi M, Mosavat F, Razmara F, Soley-mani B. Comparison of the effect of Ibuprofenand slow-released Diclofenac Sodium in con-trolling post endodontic pain. J Dent Tehran Uni Med Sci. 2010, 22: 185-91.
[43]  Negm MM. Effect of intracanal use of nonsteroidal anti-inflammatory agents on post-treatment endodontic pain. Oral Surg Oral Med Oral Pathol. 1994, 77(5): 507-13.
[44]  Kristiansen JE, Hendricks O, Delvin T, Butterworth TS, Aagaard L, Christensen JB, et al. Reversal of resistance in microorganisms by help of non-antibiotics. J Antimicrob Che-mother. 2007, 59(6): 1271-9.
[45]  Dutta NK, Mazumdar K, Seok SH, Park JH. The anti-inflammatory drug Diclofenac retains antilisterial activity in vivo. Lett Appl Microbiol. 2008, 47(2): 106-11.
[46]  Dutta NK, Mazumdar K, Dastidar SG, Park JH. Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice. Int J Anti-microb Agents. 2007, 30(4): 336-40.
[47]  Dutta NK, Kumar KA, Mazumdar K, Das-tidar SG. In vitro and in vivo antimycobacteri-al activity of antiinflammatory drug, diclofenac sodium. Indian J Exp Biol. 2004, 42(9): 922-7.
[48]  Dutta NK, Annadurai S, Mazumdar K, Dastidar SG, Kristiansen JE, Molnar J, et al. Potential management of resistant microbial infections with a novel non-antibiotic: the anti-inflammatory drug diclofenac sodium. Int J Antimicrob Agents. 2007 Sep; 30(3): 242-9.
[49]  Dastidar SG, Ganguly K, Chaudhuri K, Chakrabarty AN. The anti-bacterial action of diclofenac shown by inhibition of DNA syn-thesis. Int J Antimicrob Agents. 2000, 4(3): 249-51.
[50]  Negm MM. Intracanal use of a corticosteroid-antibiotic compound for the management of post treatment endodontic pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001, 92(4): 435-9.
[51]  Ehrmann EH, Messer HH, Adams GG. The relationship of intracanal medicaments to postoperative pain in endodontics. Int Endod J. 2003, 36(12): 868-75.
[52]  Mazumdar K. Dastidar S.G., Park J. H., et al. The anti-infl amatory non-antibiotic helper compound diclofenac: an antibacterial drug target. Eur. J. Clin. Microbiol. Infect. Dis. 2009. 28 (8) 881-891.
[53]  AL-Janabi A.S. In vitro antibacterial activity of ibuprofen and acetaminophen. J. Global Infect. Dis. 2010. 2. 105-108.
[54]  AL-Janabi A.S. Comparison of disc diffusion assay with spectrophotometer technique for antibacterial activity of diclofenac sodium, indomethacin and mefenamic acid. Asian J. Pharm. 2009. 3: 148-52.
[55]   Byrne S.T., Denkin S.M., Zhang Y. Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. J.Antimicrob. Chemother. 2006, 59. 313-316.
[56]  Van der Flier M., Geelen S.P., Kimpen J.L. Anti-infl ammatory adjuvant agents in bacterial meningitis. Curr. Med. Chem. 2002, 1. 55-62.